Findings

What do systematic reviews say?

119 questions · 120 findings · 9 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 51 · 42.5%GRADE not reported 5 · 4.2%Very low 29 · 24.2%Low 29 · 24.2%Moderate 6 · 5%High 0 · 0%

Hypertonic saline vs amiloride

All‐cause mortality · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs amiloride

Measures of sputum clearance · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Hypertonic saline vs amiloride

Pulmonary exacerbations · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs amiloride

Adverse events · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®)

FEV1: short term · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®)

FEV1 (L) · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®)

LCI · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®)

All‐cause mortality · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®)

Measures of sputum clearance · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 29 participants
Very low

Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®)

Pulmonary exacerbations · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 29 participants
Very low

Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®)

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 29 participants
Very low

Hypertonic saline vs mannitol

FEV1: short term · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Hypertonic saline vs mannitol

FEV1 (L) · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs mannitol

LCI · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs mannitol

All‐cause mortality · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs mannitol

Measures of sputum clearance · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Hypertonic saline vs mannitol

Pulmonary exacerbations · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs mannitol

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Hypertonic saline vs other intracranial pressure‐lowering agents

Mortality (short‐term) · people with acute traumatic brain injury

It is very uncertain whether hypertonic saline changes mortality (short‐term) compared with other intracranial pressure‐lowering agents (very low certainty).

1 finding from 1 review

Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury 2020 · Cochrane Headline outcomes only
RR 0.33
2 studies · 70 participants
Very low

Hypertonic saline vs other intracranial pressure‐lowering agents

Mortality at 6 months · people with acute traumatic brain injury

It is very uncertain whether hypertonic saline changes mortality at 6 months compared with other intracranial pressure‐lowering agents (very low certainty).

1 finding from 1 review

Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury 2020 · Cochrane Headline outcomes only
RR 0.84 [0.46, 1.55]
2 studies · 85 participants
Very low